Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Q3 2026 Earnings Presentation
22 slides from Legend Biotech's earnings presentation, Nov 10, 2026
Slide 1: Third Quarter 2026 Financial Results & Corporate Update
November 10, 2026 Third Quarter 2026 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes 1
Slide 2: Agenda
1 Opening Remarks 2 Q3 2026 Highlights & Recent Accomplishments Agenda 3 4 Pipeline CARVYKTI® Performance Overview 5 Financial Performance 6 Q&A 2 This presentation is for investor relations purposes only - Not for product promotional purposes
Slide 3: Presenters: Ingrid Zhang, Alan Bash, Carlos Santos
Ingrid Zhang Alan Bash Carlos Santos Chief Executive Officer President, CARVYKTI® Chief Financial Officer 3 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 4: Forward-looking Statements
Forward-looking Statements This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the submissions with the FDA, the EMA and other regulatory authorities; expected results and “Company”) solely for information purpose and does not contain all relevant information timin
Slide 5: Non-IFRS financial metrics
Non-IFRS financial metrics This presentation refers to certain non-IFRS financial metrics. We use Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share (which we sometimes refer to as “Adjusted EPS”, or “ANI per Share”, respectively) as performance metrics. Adjusted Net Income (Loss) a
Slide 6: Ingrid Zhang
Ingrid Zhang Chief Executive Officer 6 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 7: Q3 2026 Highlights & Recent Accomplishments
Q3 2026 Highlights & Recent Accomplishments Q3 2026 Highlights • Appointed Ingrid Zhang Chief Executive Officer • CARVYKTI® Net Trade Sales grew 36% YoY1 to $710M • 19% YoY growth in US • 86% YoY growth OUS • CARVYKTI® is launched in 20 global markets, with 3732 global activated CARVYKTI® treatment
Slide 8: Earlier Use of CARVYKTI May Increase 5-Year PFS and OS
Earlier Use of CARVYKTI May Increase 5-Year PFS9 and OS8 Based on Data Presented at IMS 2026 Numerically higher PFS and OS in 1-3 pLOT7 (CARTITUDE-2 Cohort A) than in ≥3 pLOT (CARTITUDE-1) CARTITUDE-2 Cohort A (N=20), PFS OS 1-3 prior LOT6 100 100 5-y OS 5-y PFS 1/2 of Patients progression free (%)
Slide 9: Advancing a Robust, Differentiated Cell Therapy Pipeline
Advancing a Robust, Differentiated Cell Therapy Pipeline Program Target Indication Pre-Clinical Phase I Phase II Phase III NDA Current Status Partner CARVYKTI®: BCMA-directed Autologous Therapy NDMM (Front-line) (Transplant Not Intended) (CARTITUDE-5)(1) Multi-Regional Clinical Trial Patient follow-
Slide 10: In Vivo Pipeline Programs
In Vivo Pipeline Programs Leveraging Stand-Alone Cell Therapy Leadership in In Vivo LB2501 1 • Encouraging clinical activity from IIT trial presented at 2026 EHA Congress • Favorable safety profile with 100% ORR1 and CR rate (8/8) at DL22, out of 19 patients across 3 dose levels with a median follow
Slide 11: Well Positioned For Long-Term Growth
Well Positioned For Long-Term Growth $710M ~$853 Million 14 Profitable1 Q3 2026 CARVYKTI Net Trade Sales Cash Position2 Pipeline Programs CAR-T Leadership in MM3 Cell Therapy Innovation Durable Global Business • CARVYKTI® is the top-selling CAR-T • Advancing next generation cell • ~$853 Million in C
Slide 12: Alan Bash
Alan Bash President, CARVYKTI® 12 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 13: CARVYKTI Sales Highlights
CARVYKTI® Sales Highlights Expanding market penetration and earlier-line adoption represent a substantial and durable growth opportunity CARVYKTI® Net Trade Sales ($MM) YoY Growth1 QoQ Growth2 U.S. 19% 0% +36% growth to $710M in Q3’26 vs. $524M in Q3’25 800 OUS3 86% 29% 700 Global4 36% 8% 238 600 18
Slide 14: Strong Earlier Line Expansion Progress in the U.S.
Strong Earlier Line Expansion Progress in the U.S. 50% of Apheresed Patients in the U.S. were 2L1 - 3L2 in Q3 2026 1Q25 Apheresed 1Q26 Apheresed 3Q26 Apheresed Patients in U.S. Patients in U.S. Patients in U.S. 2 + 3L MM 5L+ MM Patients 5L+ MM Patients 5L+ MM 29% 2 + 3L MM Patients 26% Patients Pati
Slide 15: Updated NCCN Guidelines: Considerations for Myeloma Therapy
Updated NCCN Guidelines: Considerations for Myeloma Therapy National Comprehensive Cancer Network (NCCN) Guidelines Update • All Patients with Myeloma should be referred to a T-cell therapy capable center at the time of first relapse for consideration of available therapies • When both BCMA CAR-T an
Slide 16: Carlos Santos
Carlos Santos Chief Financial Officer 16 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 17: Progress Towards Sustainable Profitability in 2026
Progress Towards Sustainable Profitability in 2026 Strong underlying demand growth, with Operating Margin improving from -142% in 2Q23 to 6%1 in 3Q26 450 150% Non-IFRS Adjusted Net Income/(Loss) (USD $M) 32% y/y Growth 63 56 400 100% 350 50% Operating Margin (%) 300 -11 -33 Revenue ($MM) 250 0% 200
Slide 18: Q3 2026 Financial Highlights
Q3 2026 Financial Highlights $ in millions (except per share) Q3 2026 Q3 2025 Change Driving Operating Leverage Over Time Collaboration Revenue 353.2 261.8 35% o Significant revenue growth of 32% YoY License & Other Revenue 6.3 10.6 -41% o Gross margin improved to 58%, mainly driven by improved labo
Slide 19: Expected Profitability and Strong Balance Sheet for Business Sustainability
Expected Profitability and Strong Balance Sheet for Business Sustainability 2026 Goals Investment Priorities Balance Sheet Strength ✓ 3/4 of CARVYKTI® orders • Advancing in vivo CAR-T • ~$853 million in Cash, Cash from 2-4L pipeline programs Equivalents and Time ✓ IND clearance for LB2501 • Focused,
Slide 20: Q&A
Q&A Ingrid Zhang Alan Bash Carlos Santos Yuhong Qiu Chief Executive Officer President, CARVYKTI® Chief Financial Officer Interim Head of R&D 20 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 21: Thank you!
Thank you! 21 This presentation is for investor relations purposes only - Not for product promotional purposes
Slide 22: Reconciliation of IFRS to Non-IFRS Metrics
Reconciliation of IFRS to Non-IFRS Metrics Three months ended September 30, ($ in millions, except per share data) 2026 2025 Net income (loss) 51.7 (39.6) Depreciation and amortization 11.0 6.0 Share-based compensation (9.6) 15.0 Impairment loss (included in other operating expense) 0 0 Unrealized f